In CLL, only a few recurrent lesions were initially identified and associated with clinical prognosis, such as mutations of the tumor protein 53 gene (TP53) or chromosomal 17p13 deletions abrogating p53 expression [25],[26]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.